ProKidney Corp. Class A

Stage 1 · Basing · week 5

As of Oct 22, 2026, ProKidney is in Stage 1, the basing phase, now in week 5 (since Sep 22, 2026). It closed at $1.43, 55.6% below its 52-week high and below its 200-day average, which is falling.

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. More about the company

$1.43

-0.69% today

$571M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is PROK early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 30w

S4 37w

S4 31w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 2w → S3 3w → S4 30w → S1 8w → S2 6w → S3 13w → S4 37w → S1 2w → S2 10w → S3 3w → S2 6w → S3 11w → S4 31w → S1 4w current

Total tracked: 166 weeks across 14 stage runs.

PROK among Biotechnology383rd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…383	PROKProKidney Corp. Class A	Stage 1 · wk 5	20	−13.3%

vs 52W High

-55.6%

$1.33 lo$3.22 hi

55.6% below 52W high

Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.

Stage Maturity

Week 5

1w13w26w

Week 5, early base

How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.

vs 200 DMA

-22.5%

200 DMA: $1.85 · sloping down

Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.

Rel Volume

0.41x

vs 50-day avg

Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-13.3%

-4.7%

-28.5%

YTD

-35.9%

-56.7%

Scan Membership

Breakout Watch

Latest: 2024-06-10

5 appearances in last 60 days. First seen: 2022-04-13.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S1

Wk 5 · Vol 0.41x

2026-10-21S1

Wk 5 · Vol 0.38x

2026-10-20S1

Wk 5 · Vol 1.03x

2026-10-19S1

Wk 4 · Vol 0.67x

2026-10-16S1

Wk 4 · Vol 1.17x

2026-10-15S1

Wk 4 · Vol 0.78x

2026-10-14S1

Wk 4 · Vol 1.54x

2026-10-13S1

Wk 4 · Vol 1.17x

2026-10-12S1

Wk 3 · Vol 0.44x

2026-10-09S1

Wk 3 · Vol 1.02x

2026-10-08S1

Wk 3 · Vol 0.84x

2026-10-07S1

Wk 3 · Vol 0.62x

Moving averages & range

50 DMA

$1.66

200 DMA

$1.85

52W High

$3.22

52W Low

$1.33

5D Low

$1.33

Resistance levels (recent highs)

20d High

$1.74

60d High

$2.01

120d High

$2.04

250d High

$3.22

Next resistance

+21.7%

to 20d High

ROE

-59.0%

Profit margin 0.0%

Dividend Yield

0.00%

P/B -0.3

ProKidney: quick answers

What stage is ProKidney in?

As of Oct 22, 2026, ProKidney (PROK) is in Stage 1, the basing phase. It entered Stage 1 on Sep 22, 2026 and is in week 5. What the four stages mean

Is ProKidney in an uptrend?

Not yet. ProKidney is in Stage 1, a base that can come before an uptrend. It trades 22.5% below its 200-day average, which is falling.

How far is ProKidney from its 52-week high?

ProKidney closed at $1.43 on Oct 22, 2026, 55.6% below its 52-week high of $3.22. Its 52-week low is $1.33.

How has ProKidney performed over the past year?

As of Oct 22, 2026, ProKidney is down 56.7% over the past year and down 35.9% so far in 2026.

Which sector and industry is ProKidney in?

ProKidney is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.